Peter Mac achieves ten from ten in Tour de Cure grants
14 December 2023
The Tour de Cure released the outcomes of their 2023 Grant Round and Peter Mac achieved a remarkable 100 percent success rate on full applications!
Ten research projects will be funded equating to almost $800,000 in research funding.
Four Peter Mac Research Students were also awarded Tour de Cure PhD scholarships valued at $10,000 each.
Professor Ricky Johnstone, Executive Director of Cancer Research said that he was delighted at the very high success rate and was pleased to see the gender split in awarded grants was 60 percent female and 40 percent male.
“Our grant success this year has been phenomenal and really is a testament to everyone involved which includes not only the researchers but all the support staff, the grants team and our consumers.
“Thank you to the Tour de Cure for their support and vision in funding cancer research.
“I look forward to seeing each of these projects advance our understanding of cancer and the best way to treat it,” said Professor Johnstone.
Details of projects funded are listed below.
- Professor Ilia Voskoboinik - ‘Understanding and managing common severe side-effects of CAR T cell therapy in Acute Lymphoblastic Leukaemia’
- Professor Mei Krishnasamy – ‘Improving outcomes for cancer patients from culturally and linguistically diverse backgrounds through co-design’
- Dr Mathieu Gaudreault – ‘Next-generation radiotherapy treatment planning using artificial intelligence and deep learning’
- Associate Professor Prof Paul Beavis – ‘Enhancing the metabolic fitness of Chimeric antigen receptor (CAR) T cells for improved treatment of cancer’
- Professor Belinda Parker – ‘Development of a novel microfluidic biochamber that supports the growth of patient-derived bone metastases for preclinical drug screening’
- Professor Kelly -Anne Phillips – ‘Preventing Breast Cancer With Medications: Bridging the Evidence-Implementation Gap’
- Professor Jeanne Tie – ‘Exploring the Utility of Peritoneal Tumour DNA to Detect Clinically Occult Peritoneal Metastasis in Locally Advanced Colorectal Cancer’
- Professor Alexander Heriot – ‘The PREDICTORG Trial: PeRsonalisED Intraperitoneal Chemotherapy for patients with resecTable colorectal peritoneal metastases: an all-Australian multicentre trial utilising patient-derived tumour-ORGanoids to facilitate precision medicine’
- Dr Reem Saleh – ‘Targeting melanoma cell plasticity to overcome targeted therapy resistance’
- Dr Rachel Delahunty – ‘Translating TRACEBACK into clinical practice’